Westenius E, Conner P, Pettersson M, Sahlin E, Papadogiannakis N, Lindstrand A, Iwarsson E
Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.
Department of Clinical Genetics and Genomics, Karolinska University Hospital, Stockholm, Sweden.
Ultrasound Obstet Gynecol. 2024 May;63(5):658-663. doi: 10.1002/uog.27592. Epub 2024 Apr 14.
To investigate the diagnostic yield of trio whole-genome sequencing (WGS) in fetuses with various congenital malformations referred to a tertiary center for prenatal diagnosis.
In this prospective study, 50 pregnancies with different congenital malformations, negative for trisomies and causative copy-number variants, were analyzed further with fetal-parental trio WGS analysis. Parents were eligible for inclusion if they accepted further investigation following the detection of isolated or multiple malformations on prenatal ultrasound. Cases with isolated increased nuchal translucency, gamete donation or multiple pregnancy were excluded. WGS with the Illumina Inc. 30× polymerase-chain-reaction-free short-read sequencing included analysis of single-nucleotide variants, insertions and deletions, structural variants, short tandem repeats and copy-number identification of SMN1 and SMN2 genes.
A molecular diagnosis was achieved in 13/50 (26%) cases. Causative sequence variants were identified in 12 genes: FGFR3 (n = 2), ACTA1 (n = 1), CDH2 (n = 1), COL1A2 (n = 1), DHCR7 (n = 1), EYA1 (n = 1), FBXO11 (n = 1), FRAS1 (n = 1), L1CAM (n = 1), OFD1 (n = 1), PDHA1 (n = 1) and SOX9 (n = 1). The phenotypes of the cases were divided into different groups, with the following diagnostic yields: skeletal malformation (4/9 (44%)), multisystem malformation (3/7 (43%)), central nervous system malformation (5/15 (33%)) and thoracic malformation (1/10 (10%)). Additionally, two cases carried variants that were considered potentially clinically relevant, even though they were assessed as variants of uncertain significance, according to the guidelines provided by the American College of Medical Genetics and Genomics. Overall, we identified a causative or potentially clinically relevant variant in 15/50 (30%) cases.
We demonstrate a diagnostic yield of 26% with clinical WGS in prenatally detected congenital malformations. This study emphasizes the benefits that WGS can bring to the diagnosis of fetal structural anomalies. It is important to note that causative chromosomal aberrations were excluded from our cohort before WGS. As chromosomal aberrations are a well-known cause of prenatally detected congenital malformations, future studies using WGS as a primary diagnostic test, including assessment of chromosomal aberrations, may show that the detection rate exceeds the diagnostic yield of this study. WGS can add clinically relevant information, explaining the underlying cause of the fetal anomaly, which will provide information concerning the specific prognosis of the condition, as well as estimate the risk of recurrence. A genetic diagnosis can also provide more reproductive choice for future pregnancies. © 2024 The Authors. Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd on behalf of International Society of Ultrasound in Obstetrics and Gynecology.
研究三联体全基因组测序(WGS)在转诊至三级产前诊断中心的各种先天性畸形胎儿中的诊断率。
在这项前瞻性研究中,对50例不同先天性畸形且三体和致病性拷贝数变异检测结果为阴性的妊娠进行了进一步的胎儿-父母三联体WGS分析。如果父母在产前超声检查发现孤立或多发畸形后接受进一步检查,则符合纳入标准。孤立性颈部半透明层增厚、配子捐赠或多胎妊娠的病例被排除。使用Illumina公司的30×无聚合酶链反应短读长测序进行WGS,包括单核苷酸变异、插入和缺失、结构变异、短串联重复序列分析以及SMN1和SMN2基因的拷贝数鉴定。
50例中有13例(26%)获得了分子诊断。在12个基因中鉴定出致病性序列变异:FGFR3(n = 2)、ACTA1(n = 1)、CDH2(n = 1)、COL1A2(n = 1)、DHCR7(n = 1)、EYA1(n = 1)、FBXO11(n = 1)、FRAS1(n = 1)、L1CAM(n = 1)、OFD1(n = 1)、PDHA1(n = 1)和SOX9(n = 1)。病例表型分为不同组,诊断率如下:骨骼畸形(4/9(44%))、多系统畸形(3/7(43%))、中枢神经系统畸形(5/15(33%))和胸部畸形(1/10(10%))。此外,根据美国医学遗传学与基因组学学会提供的指南,有2例携带的变异虽被评估为意义未明的变异,但被认为可能具有临床相关性。总体而言,我们在50例中有15例(30%)鉴定出致病性或可能具有临床相关性的变异。
我们证明临床WGS在产前检测到的先天性畸形中的诊断率为26%。本研究强调了WGS对胎儿结构异常诊断的益处。需要注意的是,在WGS之前我们的队列已排除致病性染色体畸变。由于染色体畸变是产前检测到的先天性畸形的常见原因,未来将WGS作为主要诊断测试的研究,包括对染色体畸变的评估,可能会显示检出率超过本研究的诊断率。WGS可以增加临床相关信息,解释胎儿异常的潜在原因,这将提供有关病情具体预后的信息,并估计复发风险。基因诊断还可以为未来妊娠提供更多的生育选择。© 2024作者。由John Wiley & Sons Ltd代表国际妇产科超声学会出版的《妇产科超声》。